Source: Wellteq
  • Wellteq Digital Health (WTEQ) has signed an arrangement agreement with Advanced Human Imaging Ltd. (ASX: AHI)
  • Wellteq shareholders will receive one ordinary share of AHI for every six Wellteq common shares
  • AHI has agreed to advance up to A$1,200,000 to Wellteq
  • AHI is a provider of smartphone-based human scanning technology
  • Wellteq is a leading global provider of personalized digital health and wellness solutions
  • Wellteq Digital Health Inc (WTEQ) opened trading at C$0.02

Wellteq Digital Health (WTEQ) has signed an arrangement agreement with Advanced Human Imaging Ltd. (ASX:AHI).

Under the terms of the agreement, AHI will acquire all of the outstanding shares of Wellteq. Wellteq shareholders will receive one ordinary share of AHI for every six Wellteq common shares.

AHI will issue a total of approximately 17,811,508 shares for 100 per cent of Wellteq’s issued shares.

AHI has agreed to advance up to A$1,200,000 to Wellteq. The loan will be advanced in tranches not exceeding A$200,000. Amounts advanced under the loan will be due in six months and will bear interest at a rate of 10 per cent per annum.

AHI is a provider of smartphone-based human scanning technology, with a diverse range of data-driven applications in fitness, mHealth, life & health Insurance, and apparel.

Wellteq is a leading global provider of personalized digital health and wellness solutions. 

Wellteq Digital Health Inc (WTEQ) opened trading at C$0.02.


More From The Market Online

Buzz on the Bullboards: Looking for volatility-proof stocks?

Investors saw developments in Canadian and U.S. stock markets, with attention on decisions made by central banks and moves in key sectors.
Scientific labratory

How a small-cap tech stock is broadening MRI technology 

Nanalysis Scientific (TSXV:NSCI) develops and makes compact MRI and nuclear magnetic resonance devices for clinical, lab and industrial use.

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.